BioAtla Investor Presentation Deck

CAB-AXL (BA3011) NSCLC Randomized Registrational Study Design Two Potentially Registrational Paths Enabled via the FDA Type C Meeting 2nd Line + Open-label; control: docetaxel Patients with NSCLC who have been previously treated with at least one prior line of therapy for metastatic disease Dual primary endpoints: Progression Free Survival and Overall Survival ● ● 3rd Line + Blinded; control: chemo monotherapy Patients with NSCLC who have been previously treated with at least two prior lines of therapy for metastatic disease Primary endpoint: Overall Survival ● ● ● bicatla BioAtla| Overview 41

View entire presentation